ライフサイエンスコーパス: viral envelope protein

1 able to bind and neutralize a widely mutated viral envelope protein.

2 hitosan (chi) to replace the function of the viral envelope protein.

3 of folding instability (BiP binding) of the viral envelope protein.

4 complemented by expression of a heterologous viral envelope protein.

5 ty of gp41, the transmembrane subunit of the viral envelope protein.

6 e viral lumen, as a C-terminal fusion on the viral envelope protein.

7 ecretary pathway for proteolytic cleavage of viral envelope protein.

8 ing intense selection on this segment of the viral envelope protein.

9 he membrane and hence its accessibility to a viral envelope protein.

10 LV-A), induces conformational changes in the viral envelope protein.

11 timated binding constant of the receptor and viral envelope protein.

12 efficient activation of this pH-independent viral envelope protein.

13 rocessing and cell surface expression of the viral envelope protein.

14 va is essential for efficient binding to the viral envelope protein.

15 ntracellular membrane compartment containing viral envelope proteins.

16 proposals for a general fusion mechanism for viral envelope proteins.

17 lowed M1 particle budding without additional viral envelope proteins.

18 likely required for direct interaction with viral envelope proteins.

19 kinesin and the cytoplasmic tails from five viral envelope proteins.

20 r and conformational epitopes throughout the viral envelope proteins.

21 ion molecular sizing method, to the study of viral envelope proteins.

22 surface receptors and appropriately modified viral envelope proteins.

23 study of HBV tissue tropism conferred by the viral envelope proteins.

24 Nef on infectivity in the context of various viral envelope proteins.

25 Hypervariable region 1 (HVR1) within viral envelope protein 2 (E2) is involved in the usage o

26 e measure how single amino acid mutations in viral envelope protein affect neutralizing antibodies wi

27 nown to be determined by the sequence of the viral envelope protein, although the nature of the neuro

28 e first example for any RNA virus in which a viral envelope protein and a known viral RNA packaging s

29 Antagonists targeting the interaction of the viral envelope protein and receptors on the cell surface

30 , permitting sufficient affinity between the viral envelope protein and the antibody to neutralize th

31 governed in part by interactions between the viral envelope protein and the cellular receptors.

32 to perinuclear, neuronal regions expressing viral envelope protein and the endoplasmic reticulum (ER

33 ry hypothesize that interactions between the viral envelope protein and the host receptor(s) induce c

34 arget cells by forming a complex between the viral envelope protein and two cell-surface membrane rec

35 that involves multiple interactions between viral envelope proteins and cellular receptors.

36 ms of receptor-mediated interactions between viral envelope proteins and host cell receptors at the s

37 ells and point out that interactions between viral envelope proteins and host cell receptors can have

38 charide sequence offers the binding site for viral envelope proteins and plays critical roles in assi

39 so-called "mature" NCs) are enveloped by the viral envelope proteins and secreted as virions; "immatu

40 compatibilities of analogous or orthologous viral envelope proteins, and it could have important bio

41 lights the fact that interactions of M1 with viral envelope proteins are essential to direct M1 to th

42 Glycosylated viral envelope proteins are known to be important for th

43 Since viral envelope proteins are often critical for productio

44 this approach, the transmembrane domains of viral envelope proteins are selectively targeted by the

45 The transmembrane subunits of viral envelope proteins are thought to perform all of th

46 other tegument proteins in the cytoplasm or viral envelope proteins at the site of final envelopment

47 Accumulation of the viral envelope proteins at this compartment is a prerequ

48 artment (ERGIC) requires accumulation of the viral envelope proteins at this point in the secretory p

49 d the intracellular trafficking of two model viral envelope proteins (baculovirus GP64 and vesicular

50 tu, we have ascertained that the loss of the viral envelope protein BDLF2 had little effect on the EB

51 g MERS-CoV.IMPORTANCEProteolytic cleavage of viral envelope proteins by host cell proteases is essent

52 first such interaction is the recognition of viral envelope proteins by surface receptors that normal

53 Viral envelope proteins catalyze this critical membrane

54 red membrane fusion reaction mediated by the viral envelope protein E.

55 Neutralizing antibodies are directed to the viral envelope protein (E) and an accepted correlate of

56 stem drives the transmembrane anchor of the viral envelope protein (E) toward the fusion loop, burie

57 The necessity of detecting antibodies to viral envelope proteins (E1 and E2) and to different gen

58 Recently, the crystal structure of the viral envelope protein E2 region was resolved as well as

59 ence is influenced by the interaction of the viral envelope protein E2 with heparan sulfate (HS) prot

60 Our results indicate that these viral envelope proteins encode the requisite information

61 The viral envelope protein (ENV) facilitates the earliest ev

62 egion 1 (V1) of the surface component of the viral envelope protein (Env-SU).

63 g antibodies elicited by HIV-1 coevolve with viral envelope proteins (Env) in distinctive patterns, i

64 the extent and importance of endocytosis of viral envelope proteins from the cell surface.

65 s, HIV, is the formation of a complex of the viral envelope protein gp120 and its human receptor CD4.

66 human immunodeficiency virus type 1 (HIV-1) viral envelope protein gp120 and proposed to function as

67 -azaindole core heterocycles that target the viral envelope protein gp120 has been prepared.

68 dent dorsal root ganglia (DRG) cultures, HIV viral envelope protein gp120 results in neurotoxicity an

69 analysis of the V1/V2 and V3 regions of the viral envelope protein gp120 revealed that the more effi

70 initial infection depends on binding of the viral envelope protein gp120 to CD4 on the cell surface,

71 involves sequential interactions between the viral envelope protein, gp120, cell surface CD4, and a G

72 The viral envelope protein, gp120, is toxic to neurons, indu

73 ween specific cell surface receptors and the viral envelope protein, gp120.

74 Here, we use influenza viral envelope protein hemagglutinin (HA(0)) to test the

75 ated to account for antigenic changes in the viral envelope protein, hemagglutinin (HA).

76 119E, and R169P mutations in the S domain of viral envelope proteins impair virion secretion and that

77 While much is known regarding trafficking of viral envelope proteins in mammalian cells, little is kn

78 s expressed, there were increased amounts of viral envelope proteins, including A33, A36, B5, and F13

79 irus (SARS-CoV) synthesizes several putative viral envelope proteins, including the spike (S), membra

80 ased vectors pseudotyped with many different viral envelope proteins, including VSV-G, while the same

81 ctions between the host cell receptor(s) and viral envelope protein induce structural changes in the

82 0 and the leucine zipper (LZ) region of gp41 viral envelope proteins interact cooperatively to determ

83 s, as several reports have revealed that the viral envelope proteins interact with the cellular TNF r

84 llular compartment in which specific IgA and viral envelope proteins interact, further strengthening

85 s with nanosecond dephasing times reflecting viral envelope protein interactions.

86 The viral envelope protein interacts with host cells.

87 d mixing, but pH-dependent redistribution of viral envelope proteins into the target cell membrane wa

88 mbly that result in the incorporation of the viral envelope proteins into virions.

89 unity to characterize immunogenic domains on viral envelope proteins involved in entry into target ce

90 In HIV the viral envelope protein is processed by a host cell prote

91 N-linked glycosylation of viral envelope proteins is a key mechanism for such evas

92 as been associated in part with variation in viral envelope proteins leading to antigenic variation a

93 ve two alternative fates: (i) envelopment by viral envelope proteins, leading to secretion extracellu

94 It has been shown that the large viral envelope protein limits the intracellular amplific

95 For this to occur, the viral envelope proteins must be efficiently targeted to

96 rs, blood-clotting components, and even many viral envelope proteins) occurring in almost all eukaryo

97 or direct CD4-independent association of the viral envelope protein of the HIV-1 strain III with the

98 heparin binding to many proteins, including viral envelope proteins, protein tyrosine phosphatases,

99 tion activity results for two panels bearing viral envelope proteins representing either an intergeno

100 and R169P substitutions in the S domains of viral envelope proteins, respectively, without modifying

101 The viral envelope protein, SFFV gp55, forms a complex with

102 infection, decreasing the copy number of the viral envelope proteins shifts the dominant infection pa

103 The fusogen is constructed by modifying viral envelope proteins, so that they lack the ability t

104 o be initiated by inefficient folding of its viral envelope protein, suggesting that the neurodegener

105 sed in these analyses differ solely in their viral envelope proteins, suggesting that the block to XM

106 All isolates from recent outbreaks encode a viral envelope protein that is glycosylated, whereas man

107 Influenza virus hemagglutinin (HA) is the viral envelope protein that mediates viral attachment to

108 form a trimeric coiled coil, reminiscent of viral envelope proteins that direct homotypic membrane f

109 very little of the middle and small surface (viral envelope) proteins that are translated from these

110 rulence is determined by the sequence of the viral envelope protein, though the specific role of this

111 nitiates with binding of the pre-S domain of viral envelope protein to surface receptors present on t

112 Therefore, at least three viral envelope proteins, Us9, gE, and gI, function toget

113 be pseudotyped by introducing a heterologous viral envelope protein (vesicular stomatitis virus G pro

114 In this study, we asked whether two viral envelope proteins (VSV G and baculovirus GP64) alo

115 t of the R peptide on the fusion activity of viral envelope proteins, we expressed simian immunodefic

116 ssue-specific polarized trafficking of these viral envelope proteins, we identified one of the virus-

117 tes were detected in the pre-S domain of the viral envelope protein, which is believed to determine v

118 Enveloped delivery modalities use viral envelope proteins, which determine tropism and ind

119 IV-1) requires functional interaction of the viral envelope protein with a coreceptor belonging to th

120 y requires the functional interaction of the viral envelope protein with both CD4 and the CCR-5 corec

121 cells requires the sequential engagement of viral envelope protein with CD4 and coreceptor, we propo

122 ltistep process involving the interaction of viral envelope proteins with cell surface receptors.

123 oteins required specific interactions of the viral envelope proteins with the internal capsid protein

124 ed a common theme of a sequential binding of viral envelope proteins with two coreceptors to mediate

125 sts by searching for the accumulation of the viral envelope protein, ZIKV ribonucleic acid (RNA), and